Literature DB >> 9874718

Artificial neural networks applied to the in vitro-in vivo correlation of an extended-release formulation: initial trials and experience.

J A Dowell1, A Hussain, J Devane, D Young.   

Abstract

Artificial neural networks applied to in vitro-in vivo correlations (ANN-IVIVC) have the potential to be a reliable predictive tool that overcomes some of the difficulties associated with classical regression methods, principally, that of providing an a priori specification of the regression equation structure. A number of unique ANN configurations are presented, that have been evaluated for their ability to determine an IVIVC from different formulations of the same product. Configuration variables included a combination of architectural structures, learning algorithms, and input-output association structures. The initial training set consisted of two formulations and included the dissolution from each of the six cells in the dissolution bath as inputs, with associated outputs consisting of 1512 pharmacokinetic time points from nine patients enrolled in a crossover study. A third formulation IVIVC data set was used for predictive validation. Using these data, a total of 29 ANN configurations were evaluated. The ANN structures included the traditional feed forward, recurrent, jump connections, and general regression neural networks, with input-output association types consisting of the direct mapping of the dissolution profiles to the pharmacokinetic observations, mapping the individual dissolution points to the individual observations, and using a "memorative" input-output association. The ANNs were evaluated on the basis of their predictive performance, which was excellent for some of these ANN models. This work provides a basic foundation for ANN-IVIVC modeling and is the basis for continued modeling with other desirable inputs, such as formulation variables and subject demographics.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9874718     DOI: 10.1021/js970148p

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  In vitro-in vivo correlations: tricks and traps.

Authors:  J-M Cardot; B M Davit
Journal:  AAPS J       Date:  2012-05-01       Impact factor: 4.009

2.  Generalization of a prototype intelligent hybrid system for hard gelatin capsule formulation development.

Authors:  Wendy I Wilson; Yun Peng; Larry L Augsburger
Journal:  AAPS PharmSciTech       Date:  2005-10-22       Impact factor: 3.246

3.  Neuro-fuzzy models as an IVIVR tool and their applicability in generic drug development.

Authors:  Jerneja Opara; Igor Legen
Journal:  AAPS J       Date:  2014-01-30       Impact factor: 4.009

4.  In vitro- in vivo correlation's dissolution limits setting.

Authors:  B Roudier; B M Davit; E Beyssac; J-M Cardot
Journal:  Pharm Res       Date:  2014-03-28       Impact factor: 4.200

5.  Bioavailability, bioequivalence, and in vitro-in vivo correlation of oxybutynin transdermal patch in rabbits.

Authors:  Achyut Khire; Pradeep Vavia
Journal:  Drug Deliv Transl Res       Date:  2014-04       Impact factor: 4.617

6.  Modeling the pharmacokinetics and pharmacodynamics of a unique oral hypoglycemic agent using neural networks.

Authors:  Sam H Haidar; Steven B Johnson; Michael J Fossler; Ajaz S Hussain
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

7.  Generalized in vitro-in vivo relationship (IVIVR) model based on artificial neural networks.

Authors:  Aleksander Mendyk; Paweł K Tuszyński; Sebastian Polak; Renata Jachowicz
Journal:  Drug Des Devel Ther       Date:  2013-03-27       Impact factor: 4.162

8.  Artificial neural networks in evaluation and optimization of modified release solid dosage forms.

Authors:  Svetlana Ibrić; Jelena Djuriš; Jelena Parojčić; Zorica Djurić
Journal:  Pharmaceutics       Date:  2012-10-18       Impact factor: 6.321

Review 9.  State-of-the-Art Review of Artificial Neural Networks to Predict, Characterize and Optimize Pharmaceutical Formulation.

Authors:  Shan Wang; Jinwei Di; Dan Wang; Xudong Dai; Yabing Hua; Xiang Gao; Aiping Zheng; Jing Gao
Journal:  Pharmaceutics       Date:  2022-01-13       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.